Xintela ABFRA:1XT 8 EBIT per Share is €-0.01 as of Mar. 2026. GuruFocus rates FRA:1XT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 1,173 Biotechnology companies, Xintela AB ranks better than 81.67% on this metric.
Xintela AB's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 43.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 16.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Xintela AB's EBIT per Share or its related term are showing as below:
FRA:1XT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -80.5 Med: 0.75 Max: 45.4
Current: 43.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Xintela AB was 45.40% per year. The lowest was -80.50% per year. And the median was 0.75% per year.
FRA:1XT's 3-Year EBIT Growth Rate is ranked better than 81.67% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs FRA:1XT: 43.80
Xintela AB's EBIT for the
three
months ended in Mar. 2026 was €-1.04 Mil.
Xintela AB (FRA:1XT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Xintela AB EBIT per Share Related Terms
Xintela AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Xintela AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xintela AB (FRA:1XT) has a EBIT per Share of €-0.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #215 out of 1173 companies in the Biotechnology industry, placing it in the top 18.3%.
Is Xintela AB's EBIT per Share too high?
Xintela AB's current EBIT per Share is €-0.01. Based on the distribution chart, Xintela AB ranks #215 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xintela AB ranks #215 out of 1173 companies for EBIT per Share. This places Xintela AB in the top 18% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Xintela AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xintela AB's current EBIT per Share is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (FRA:1XT) has a current EBIT per Share of €-0.01. The current EBIT per Share is €-0.01. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Xintela AB (FRA:1XT), the current EBIT per Share is €-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score
Get the complete analysis for FRA:1XT
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1XT has been successfully added to your 
